Poor prognosis of heart transplant patients with end-stage renal failure

Emmanuel Villar1, Pascale Boissonnat, Laurent Sebbag

  • 1Department of Nephrology, Dialysis and Transplantation, Hospices Civils de Lyon, Lyon Sud Hospital, Claude Bernard University, France. emmanuel.villar@chu-lyon.fr

Insights

Heart transplant (HT) patients with chronic kidney disease (CKD) requiring dialysis for end-stage renal failure (ESRF) have significantly poorer survival rates compared to non-HT patients. Renal transplant is recommended as the preferred ESRF treatment for HT recipients.

Area of Science:

  • Nephrology
  • Cardiology
  • Transplantation Medicine

Background:

  • Chronic kidney disease (CKD) and end-stage renal failure (ESRF) are significant complications following heart transplantation (HT).
  • Comparing survival outcomes for heart transplant (HT) recipients versus non-HT patients initiating dialysis is crucial for understanding post-transplant complications.

Purpose of the Study:

  • To compare the survival rates of heart transplant (HT) patients with end-stage renal failure (ESRF) undergoing dialysis against non-HT patients on dialysis.
  • To identify causes of ESRF and mortality in HT patients post-dialysis initiation.

Main Methods:

  • A cohort of 539 newly dialyzed patients between 1995 and 2005 were prospectively followed.
  • Multivariate survival analysis using the Cox model was performed, adjusting for baseline characteristics.

Main Results:

  • Heart transplant (HT) patients were younger at dialysis initiation (58.6 vs. 63.0 years).
  • Calcineurin inhibitor nephrotoxicity was the primary cause of ESRF in 47.6% of HT patients.
  • Adjusted hazard ratio for death in HT vs. non-HT patients was 2.27 (P=0.003), with sudden death being more common in HT patients (33.3% vs. 10.4%).
  • Five HT patients received renal transplants and survived; only one of 16 remaining HT patients on dialysis survived.

Conclusions:

  • Heart transplant (HT) patients reaching end-stage renal failure (ESRF) exhibit poor survival on dialysis compared to non-HT patients.
  • Improved renal function management and evaluation of non-nephrotoxic immunosuppressants are necessary for CKD patients post-HT.
  • Renal transplantation should be considered the optimal ESRF treatment for HT recipients.
Abstract

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...